Urothelial Cancer

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

The EMA's CHMP has adopted a positive opinion regarding erdafitinib in patients with FGFR3+ unresectable or metastatic urothelial carcinoma.

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

Perioperative durvalumab demonstrated a statistically significant improvement in EFS and OS in muscle-invasive bladder cancer.

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

The addition of avelumab to cisplatin-based chemotherapy led to high event-free survival and overall survival rates in patients with muscle-invasive urothelial carcinoma.

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.

Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.

Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.

Petros Grivas, MD, PhD, expands on key updates in the second-line management of urothelial cancer.

Peter H. O’Donnell, MD, provides insights on key developments in bladder cancer management and how they have generated optimism within the field.

Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.